Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Net Margin (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Net Margin for 8 consecutive years, with 35.67% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 33320.0% year-over-year to 35.67%, compared with a TTM value of 78.15% through Dec 2025, up 52500.0%, and an annual FY2025 reading of 78.15%, up 52500.0% over the prior year.
  • Net Margin was 35.67% for Q4 2025 at Zevra Therapeutics, up from 2.08% in the prior quarter.
  • Across five years, Net Margin topped out at 288.46% in Q2 2025 and bottomed at 50087.5% in Q2 2022.
  • Average Net Margin over 5 years is 2683.4%, with a median of 129.32% recorded in 2021.
  • The sharpest move saw Net Margin crashed -4999128bps in 2022, then surged 5005712bps in 2023.
  • Year by year, Net Margin stood at 104.69% in 2021, then soared by 368bps to 280.42% in 2022, then crashed by -155bps to 153.96% in 2023, then tumbled by -93bps to 297.53% in 2024, then skyrocketed by 112bps to 35.67% in 2025.
  • Business Quant data shows Net Margin for ZVRA at 35.67% in Q4 2025, 2.08% in Q3 2025, and 288.46% in Q2 2025.